New Drugs on the Market in USA - SRT Forums

Arne · 05-20-2006, 05:36 AM

New Drugs To Watch

http://www.forbes.com/business/2004/...han=b4newdrugs

Keep an eye on Gardasil, new vaccine for Human Papilloma Virus, by Merck. Huge investment.
Most of us know that the Great USA was founded on Promiscuity! With the help of this new vaccine approaved by FDA yesterday, people can engage in all kinds of love, and not worry about cervical cancer. This might be a stock breaker after there lawsuits from VIOXX.
The vaccine is more effective in girls given at an earlier age. This could possibly mean that young females, will engage in Sex early in there lives.

Here is an article.

A U.S. Food and Drug Administration panel voted unanimously to approve the use of a Merck vaccine aimed at preventing cervical cancer, but long-term questions remain about how the potential breakthrough would be used.

The vaccine, Gardasil, gives patients immunity to the human papilloma virus (HPV), a sexually transmitted disease that can lead to cervical cancer.

The panel, made up mostly of academic experts, recommended the approval of the vaccine in women as young as nine. The FDA is not bound to by the advice of its panels, but it usually follows it. A final decision is expected by June 8.

It is an open question exactly how broadly Gardasil will be used, and the debate could be politically charged as it involves vaccinating young girls. Merck (nyse: MRK - news - people ) has already started running television advertisements to educate the public about the risks of HPV. Another key flashpoint in the debate will come on June 28 and 29, when a panel of experts at the Centers for Disease control will meet to consider what kinds of HPV vaccinations the CDC should recommend.

Geoffrey Porges, a biotechnology analyst at Sanford C. Bernstein, wrote in a note to investors this morning that Merck had made a forceful case for broad use of the vaccine -- including using it in young boys. Although men cannot get cervical cancer, HPV would be far less likely to spread if both girls and boys were vaccinated.

Some investors have been bidding up shares of MedImmune (nasdaq: MEDI - news - people ), the Gaithersburg, Md.-based maker of a drug for treating infections in premature infants, because the biotech has licensing agreements for key technology in the HPV vaccines of both Merck and GlaxoSmithKline (nyse: GSK - news - people ), which is close behind with a similar preventative. Australia's CSL Limited, which is not traded in the U.S., may also receive a royalty.

Bernstein's Porges estimates that MedImmune could get $175 million in 2010 royalties from both vaccines, adding 46 cents to its earnings per share; that could be worth $7 to MedImmune shares, he says. Porges estimates 2010 worldwide sales of $3.3 billion for Gardasil, compared to $940 million for Glaxo's Cervarix.